Table 2.

Dosing regimens of apixaban, dabigatran, and rivaroxaban for the prevention of stroke in patients with AF in the European Union and US

	Apixaban	Dabigatran	Rivaroxaban
European Union
Recommended dose	5 mg bid in patients with CrCl ≥30 mL/minute	150 mg bid in patients with CrCl ≥30 mL/minute	20 mg od in patients with CrCl ≥50 mL/minute
Dose adjustments	2.5 mg bid if CrCl 15–29 mL/minute; 2.5 mg bid in the presence of ≥2 of the following characteristics: • Age ≥80 years • Body weight ≤60 kg • Serum creatinine ≥1.5 mg/dL (133 μmol/L)	110 mg bid may be considered in patients with the following factors: • Age ≥80 years (or 75–80 years with high risk of bleeding) • CrCl 30–50 mL/minute with a high risk of bleeding	15 mg od if CrCl 15–49 mL/minute
Contraindicated in patients with CrCl	No contraindications but not recommended in patients with CrCl, 15 mL/minute	<30 mL/minute	No contraindications but not recommended in patients with CrCl <15 mL/minute
US
Recommended dose	5 mg bid in patients with CrCl ≥15 mL/minute	150 mg bid in patients with CrCl >30 mL/minute (unless concomitantly using P-gp inhibitors; see dose adjustments)	20 mg od in patients with CrCl >50 mL/minute
Dose adjustments	2.5 mg bid in the presence of ≥2 of the following characteristics: • Age ≥80 years • Body weight ≤60 kg • Serum creatinine ≥1.5 mg/dL (133 μmol/L)	75 mg bid if CrCl 15–30 mL/minute or in patients with CrCl 30–50 mL/minute concomitantly using P-gp inhibitors (eg, dronedarone or systemic ketoconazole)	15 mg od if CrCl 15–50 mL/minute
Contraindicated in patients with CrCl	No contraindications but not recommended in patients with CrCl <15 mL/minute	Avoid use in patients with CrCl 15–30 mL/minute and concomitantly receiving P-gp inhibitors; no recommendations are available for patients with CrCl <15 mL/minute	<15 mL/minute

Note: Data from references 2, 3, and 51–54.

Abbreviations: AF, atrial fibrillation; bid, twice daily; CrCl, creatinine clearance; od, once daily; P-gp, P-glycoprotein; US, United States.